Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 18/01/2018 Teaser-Mutationen-Primartumor.png

    Medications that target metastasing tumours

    Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
  • Article - 24/07/2017 The figure shows a model of the IDH1 complex. Two polypeptide chains (brown and light blue) form a dimer between which the substance BAY 1436032 (yellow) binds.

    Cancer medicine development as a science and industry partnership

    The German Cancer Research Center (DKFZ) and Bayer AG are collaborating on a strategic partnership focusing on the development of innovative cancer therapies. The two partners have developed an active substance which selectively blocks a mutation of a metabolic enzyme that occurs in certain types of cancer. The substance has been successfully tested in preclinical studies and is now also being tested in a clinical trial on patients with brain…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-medicine-development-as-a-science-and-industry-partnership
  • Press release - 02/02/2012 Immatics Logo

    Colorectal cancer: Phase II results with cancer vaccine IMA910 are positive

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive results from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13 tumor-associated…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-phase-ii-results-with-cancer-vaccine-ima910-are-positive
  • Press release - 29/02/2016

    Retina Implant AG Secures €26 Million Round of Private Funding

    Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced the completion of an €26 million round of private equity funding. The funding represents a significant recommitment by both Retina Implant's long-standing investors and new investors, and will be used to establish new clinical centres around the world. It will also help the company to initiate reimbursement…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/retina-implant-ag-secures-26-million-round-of-private-funding
  • Article - 07/03/2017 Seven people holding a check indicating the donated sum of 20.000.000 euros.

    KiTZ: Hopp Children’s Tumour Center at NCT Heidelberg

    The Heidelberg University Hospital and the DKFZ have established the "Hopp Children's Tumor Center at NCT Heidelberg" (KiTZ) where doctors, scientists, nursing staff and other specialists work side by side on new diagnostic and therapeutic options to help children with cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/kitz-hopp-childrens-tumour-center-at-nct-heidelberg
  • Press release - 28/05/2009 07777_de.jpg

    CureVac Begins Clinical Study with mRNA Vaccine

    CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
  • Company profile - 04/09/2017 Colour photo of Prof. Dr. François Paquet-Durand (left) and Barbara Brunnhuber (right).

    Mireca: a new drug for stopping the progression of eye diseases

    A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mireca-a-new-drug-for-stopping-the-progression-of-eye-diseases
  • Press release - 24/03/2021

    Vaccination against mutated protein tested in brain tumor patients for the first time

    Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-mutated-protein-tested-brain-tumor-patients-first-time
  • Article - 11/12/2008

    New drug that targets metastasing breast cancer in clinical phase III trial

    Protein kinases are a major focus of modern cancer research. Since it has become known that these enzymes play a role in the development of tumours, researchers around the world are concentrating on finding drugs to inhibit overactive protein kinases and prevent cancer cells from growing. One of these active substances is currently being tested at the Tumour Biology Centre in Freiburg as part of a worldwide phase III clinical trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-that-targets-metastasing-breast-cancer-in-clinical-phase-iii-trial
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial – with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Article - 21/03/2011 The molecular and cellular interactions of an antigen-presenting cell (AP cell) are highly complex.<br />

    Immunotherapy: the rocky road to clinical application

    Hans-Georg Rammensee has one major goal: he wants to contribute to the successful application of immunotherapy in clinical settings and is convinced that this will only be possible once individualised immunotherapies are used. Individualised immunotherapy refers to the induction of a specific immune response against specific tumour-associated antigens. Rammensee has made major progress in this area and is now focused on overcoming the obstacles…

    https://www.gesundheitsindustrie-bw.de/en/article/news/immunotherapy-the-rocky-road-to-clinical-application
  • Press release - 17/06/2020

    CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
  • Press release - 02/11/2011 15730_de.jpg

    Using Viruses to Fight Brain Tumors

    Parvoviruses can enter and kill cancer cells, but they do not cause disease in humans. Since 1992, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been studying these viruses with the aim of developing a viral therapy against dangerous brain tumors that are almost impossible to treat.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-viruses-to-fight-brain-tumors
  • Article - 30/08/2010 12218_de.jpg

    Bodensee Brustzentrum offers effective breast cancer prevention services

    The two Brustzentrum Bodensee (Lake Constance Breast Centre) sites at the Hospital in Constance and the Women’s Hospital in Friedrichshafen have a principal goal: to enable the best possible early detection of all types of breast cancer, to reduce the morbidity and mortality of breast cancer patients and to increase survival rates by offering ultra-modern breast cancer prevention measures.

    https://www.gesundheitsindustrie-bw.de/en/article/news/bodensee-brustzentrum-offers-effective-breast-cancer-prevention-services
  • Article - 22/11/2010 13041_de.jpg

    LEUKONET provides evidence for new therapies for CNS diseases

    The concept of evidence-based medicine stipulates that the efficacy of any therapy must be shown in large clinical studies before being used for treating patients. However this is a requirement that cannot be realistically fulfilled for rare diseases due to the small number of people affected. To redress this situation in the case of leukodystrophies rare metabolic disorders of the nervous system that affect only a small number of people in…

    https://www.gesundheitsindustrie-bw.de/en/article/news/leukonet-provides-evidence-for-new-therapies-for-cns-diseases
  • Press release - 10/01/2012 Logo apogenix

    Apogenix receives additional 2.3 million Euros BMBF grant as partner of the biotech cluster Rhine-Neckar

    The biopharmaceutical company Apogenix GmbH today announced that it has received an additional € 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101. Apogenix will use the proceeds to develop APG101 for the treatment of myelodysplastic syndromes (MDS). More specifically, the grant will be used for the production of clinical material and for the development of a…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-receives-additional-2-3-million-euros-bmbf-grant-as-partner-of-the-biotech-cluster-rhine-ne
  • Affimed GmbH - 01/07/2020 Schematische Darstellung der Kommunikation zwischen den Zellen der angeborenen und erworbenen Immunität. „innate cell engager“ aktivieren NK-Zellen und Makrophagen, die wiederum tumorspezifische T-Zellen stimulieren.

    "Innate cell engagers" to fight cancer

    In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
  • Article - 05/06/2008

    CureVac: partnership with University of Florida,

    CureVac GmbH has entered into a partnership with the Department of Urology University of Florida Gainesville U.S. to jointly advance its lead candidate CV9103 into the clinical development. The alliance covers preclinical studies and a US phase III trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-partnership-with-university-of-florida
  • Press release - 17/10/2008

    Three anti-diabetes compounds in advanced clinical testing

    Boehringer Ingelheim has three oral compounds for the treatment of diabetes type II in phase II and III of clinical development. The most advanced compound a DPP-4 inhibitor is in the final clinical phase.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-anti-diabetes-compounds-in-advanced-clinical-testing
  • Press release - 07/08/2012 Immatics Logo

    immatics announces publication of IMA901 cancer vaccine data in Nature Medicine

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
  • Article - 16/01/2012 The photo shows fifteen people standing in front of a building.

    Manfred Jung: drug discovery and the epigenetic code

    Prof. Dr. Manfred Jungs team at the University of Freiburg are chemical epigeneticists whose research involves the development of methods that enable them to identify and optimise new therapeutic drugs which are able to alter the epigenetic code of cancer and other cell types. The team use a perfidious worm for their research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/manfred-jung-drug-discovery-and-the-epigenetic-code
  • Press release - 30/07/2009

    Boehringer Ingelheim set to outpace the market again

    After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
  • Article - 18/01/2016 The photo shows two blister packs with tablets.

    New approaches in the life sciences industry: innovative strategies for courageous companies

    For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-avenues-in-the-life-sciences-industry-innovative-strategies-for-brave-companies
  • Press release - 24/01/2011 13484_de.jpg

    Synimmune - Close cooperation cuts new cancer drug development time

    A development project from Synimmune GmbH, founded in July 2010, made a big impression on the panel of assessors at the German Federal Ministry of Education and Research (BMBF). So much so, that the company was awarded EUR 2.5 million as part of the GO-Bio biotechnology start-up scheme.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/synimmune-close-cooperation-cuts-new-cancer-drug-development-time
  • Press release - 23/10/2020

    CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-preclinical-data-its-covid-19-vaccine-candidate-cvncov

Page 3 / 10

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search